Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) Operating Margin: 2011-2025

Historic Operating Margin for Adma Biologics (ADMA) over the last 11 years, with Sep 2025 value amounting to 38.01%.

  • Adma Biologics' Operating Margin rose 493.00% to 38.01% in Q3 2025 from the same period last year, while for Sep 2025 it was 34.19%, marking a year-over-year increase of 417.00%. This contributed to the annual value of 32.59% for FY2024, which is 2421.00% up from last year.
  • As of Q3 2025, Adma Biologics' Operating Margin stood at 38.01%, which was up 8.32% from 35.08% recorded in Q2 2025.
  • Adma Biologics' Operating Margin's 5-year high stood at 38.01% during Q3 2025, with a 5-year trough of -94.49% in Q1 2021.
  • Its 3-year average for Operating Margin is 23.39%, with a median of 30.38% in 2025.
  • Per our database at Business Quant, Adma Biologics' Operating Margin surged by 13,250bps in 2021 and then tumbled by 149bps in 2025.
  • Over the past 5 years, Adma Biologics' Operating Margin (Quarterly) stood at -23.98% in 2021, then surged by 1,186bps to -12.12% in 2022, then soared by 3,138bps to 19.26% in 2023, then surged by 1,334bps to 32.60% in 2024, then surged by 493bps to 38.01% in 2025.
  • Its Operating Margin was 38.01% in Q3 2025, compared to 35.08% in Q2 2025 and 30.38% in Q1 2025.